REG - ValiRx PLC - Inaphaea Co-Marketing Agreement

ValiRxAnnouncement

16/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240916:nRSP2272Ea&default-theme=true

RNS Number : 2272E  ValiRx PLC  16 September 2024

ValiRx plc

 

("ValiRx" or the "Company")

 

Inaphaea Co-Marketing Agreement

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, provides the following
update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of a co-marketing agreement (the
"Agreement") with US contract research organisation Netoids Rx Laboratories
LLC, doing business as Spanios LLC ("Spanios"), to provide Inaphaea's high
throughput drug screening services using its Patient Derived Cells ("PDC") as
a precursor to Spanios's proprietary Patient Derived Tumoroids ("PDT").

Inaphaea and Spanios will be entitled to a percentage of service royalties on
relevant contract introduced by the respective party. Both companies have also
agreed to co-market their respective services. The Agreement is for a period
of 12 months initially and may be extended in writing by mutual agreement.

 

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea,
commented "This deal with Spanios is the first co-marketing arrrangment for
Inaphaea in the US and demonstrates the synergy of our Patient Derived Cell
approach for rapid and economic screening of larger numbers of drug candidates
before transferring lead candidates into Spanios's lower throughput but higher
complexity, ex-vivo models."

Mark Eccleston, CEO of ValiRx commented "We are excited to be working with a
highly innovative partner like Spanios. Bringing therapies to market faster
requires better models for screening drugs to deliver more accurate and
translatable results. Inaphaea has focussed on the early stage of this process
where, typically, larger numbers of candidates need to be refined for
screening in disease relevant models. We can then pass on the best candidates
to Spanios for testing in their organoid platform."

Bhuvanesh Dave, PhD, Co-Founder and CEO of Spanios, commented "The partnership
with Inaphaea is a perfect fit for our joint goal of accelerating drug
development to bring therapies to patients faster. Combining Inaphaea's higher
throughput approach to candidate selection with our versatile
three-dimensional PDT drug testing platform, COMPASS (Custom Organoid
Modelling Platform for Accurate & Speedy Solutions) which is capable of
recapitulating tumor microenvironment (TME) including features of oxygenation
and immunocompetence, we can combine the best of both approaches for advancing
discovery and development pipeline."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 115 784 0026

                                                   www.valirx.com

 Dr Mark Eccleston, CEO                            info@valirx.com (about%3Ablank)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRQKPBNFBKKCCD